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Abstract
PLX4032/vemurafenib is a first-in-class small-molecule BRAFV600E inhibitor with clinical activity in patients with BRAF
mutant melanoma. Nevertheless, drug resistance develops in treated patients, and strategies to overcome primary
and acquired resistance are required. To explore the molecular mechanisms involved in primary resistance to
PLX4032, we investigated its effects on cell proliferation and signaling in a panel of 27 genetically characterized
patient-derived melanoma cell lines. Cell sensitivity to PLX4032 was dependent on BRAFV600E and independent from
other gene alterations that commonly occur in melanoma such as PTEN loss, BRAF, and MITF gene amplification.
Two cell lines lacking sensitivity to PLX4032 and harboring a different set of genetic alterations were studied as models
of primary resistance. Treatment with the MEK inhibitor UO126 but not with PLX4032 inhibited cell growth and ERK
activation. Resistance to PLX4032 was maintained after CRAF down-regulation by siRNA indicating alternative activa-
tion of MEK-ERK signaling. Genetic characterization by multiplex ligation-dependent probe amplification and analysis
of phosphotyrosine signaling by MALDI-TOF mass spectrometry analysis revealed the activation of MET and SRC sig-
naling, associated with the amplification of MET and of CTNNB1 and CCND1 genes, respectively. The combination of
PLX4032 with drugs or siRNA targetingMET was effective in inhibiting cell growth and reducing cell invasion andmigra-
tion in melanoma cells with MET amplification; similar effects were observed after targeting SRC in the other cell line,
indicating a role for MET and SRC signaling in primary resistance to PLX4032. Our results support the development of
classification of melanoma in molecular subtypes for more effective therapies.
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Introduction
Among the common gene alterations occurring in melanoma patho-
genesis, the most frequent is the T1799A transversion in the v-raf
murine sarcoma viral oncogene homolog B1 (BRAF) gene that causes
a glutamic acid substitution for valine at position 600 in the en-
coded kinase, which is detectable in approximately 50% of tumor
lesions. BRAF is a serine/threonine–specific protein kinase that
is activated by RAS G protein, which is activated downstream
of growth factor receptors, cytokines, and hormones in the RAS/
MEK/extracellular signal–regulated kinase (ERK) signaling cascade.
The V600E change activates the RAF kinase function to constitu-
tively activate the mitogen-activated protein kinase (MAPK) pathway
through the hyperactivation of ERK, which promotes cell survi-
val, proliferation, invasion, and angiogenesis. BRAF mutation acts
as a driver determining a state of “oncogene addiction,” unrespon-
sive to inhibition by MAPK/ERK kinase (MEK)–dependent feed-
back but displaying increased sensitivity to the direct inhibition of
BRAF and MEK [1]. MAPK signaling determines the cascade acti-
vation of other pathways that interact at different levels. This net-
work signals also to the phosphoinositide 3-kinase/v-akt murine
thymoma viral oncogene homolog (AKT)/mammalian target of
rapamycin pathway, which is constitutively activated in melanoma
and may offer compensatory routes to promote cell proliferation and
survival [2].
In view of the relevance of RAS/BRAF/MAPK–activated signaling
in melanoma, several inhibitors have been produced targeting the
RAF kinases, some showing selectivity for mutant BRAF, or targeting
the downstream kinase MEK. Several of these inhibitors are currently
being evaluated in clinical trials [3]. PLX4032 is an azaindole de-
rivative ATP-competitive inhibitor specific for V600E mutant BRAF
which displayed promising efficacy in preclinical studies [4–7]. Phase
1 to 2 clinical trials have shown response rates of more than 50% in
patients with melanoma carrying the BRAFV600E mutation, a result
confirmed in a phase 3 trial reporting improved rates of overall and
progression-free survival [8–10]. Despite this encouraging evidence,
the clinical results pointed at secondary resistance as a common fea-
ture of kinase-targeted drugs and a major issue for investigations.
Studies investigating the mechanisms associated to the acquisition
of resistance have reported different genetic and epigenetic altera-
tions, which promote ERK activation by MEK-dependent mecha-
nisms bypassing BRAF inhibition, detectable in tumor biopsies from
patients who developed resistance to PLX4032 treatment after clinical
response. These alterations included de novo somatic mutations in
MEK1, neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS),
or phosphatase and tensin homolog (PTEN ) genes, but not in the tar-
geted BRAF gene, as well as hyperactivation of platelet-derived growth
factor receptor β, insulin-like growth factor 1 receptor (IGF1R), and
MAP3K8 kinases [11–14].
In the current report, we focused on melanoma showing primary
resistance that were identified by screening a panel of patient-derived
genetically characterized BRAFV600E-mutated melanoma cell lines to
identify alterations that are associated with the cellular response to
PLX4032. We investigated at the genetic and molecular levels two
melanoma cell lines that displayed poor sensitivity to PLX4032 as
models of primary resistance. By genetic characterization and by using
a phosphoproteomic approach, we identified and validated further tar-
gets for pharmacological intervention and examined the effects of the
combination of PLX4032 with other kinase inhibitors as an approach
to overcome resistance.
Materials and Methods
Cells and Cellular Assays
The short-term melanoma cell lines LM4-LM41 have previously
been described [15]; LM42 and LM43 were derived from visceral
metastases and were similarly generated and characterized. The cell
line LM17R was generated by treating the parental cell line LM17
with PLX4032 (3.2 μM) for 96 hours, allowing the few surviving
cells to regrow, and repeating treatment for 11 times. MTT assays
were used to evaluate the inhibition of cell growth at 72 hours, add-
ing drugs 24 hours after cell plating. The bioluminescent ToxiLight
bioassay kit (Lonza, Valais, Switzerland) was used to measure the re-
lease of adenylate kinase (AK) from dying cells. Caspase 3 activation
was measured using the Active Caspase 3 Apoptosis Kit (Becton
Dickinson, Franklin Lakers, NJ). The analysis of the cell cycle was per-
formed by determining the DNA content distribution after propidium
iodide staining using a FACSCalibur and ModFit LT v3.1 soft-
ware. Silencing of v-raf-1 murine leukemia viral oncogene homolog 1
(CRAF) and met proto-oncogene (MET) was obtained using SMART
pool small interfering RNA (siRNA; L-003601 and L-003156;
Dharmacon, Lafayette, CO) and Lipofectamine 2000 (Gibco, Grand
Island, NY). A scrambled control was used (D-001810-10). Invasion
assays were performed as previously described [16] on cells exposed
for 24 hours to the inhibitors. Scratch wound assays were set on
confluent cell monolayer in six-well plates. The monolayer was
scratched using a sterile pipette tip, rinsed to remove detached cells,
and treated with inhibitors for 72 hours. Matrix metalloproteinase 2
and 9 (MMP-2/-9) activity was assessed using 10% SDS-PAGE gelatin
substrate zymography (Invitrogen, Carlsbad, CA) in serum-free condi-
tioned medium after concentration with Amicon Ultra 10K (Millipore,
Billerica, MA). Anti–human β1-integrin antibody (552828; Becton
Dickinson) was used with APC-conjugated anti-rat immunoglobulin G
(Jackson ImmunoResearch, Plymouth, PA) and analyzing staining
by FACS analysis. Fluorescent in situ hybridization (FISH) analysis
was performed using the probe kit D7S522/CEP7 according to the
manufacturer’s protocol (Abbott Vysis, Abbott Park, IL).
Genetic Analysis
Copy numbers of BRAF, microphthalmia-associated transcription
factor (MITF ), MET, cyclin D1 (CCND1), and β-catenin (CTNNB1)
genes in melanoma samples were determined by quantitative real-time
polymerase chain reaction (PCR) analysis using TaqMan Copy Num-
ber Assays from Applied Biosystems (Branchburg, NJ). In particular,
the copy number of BRAF gene was evaluated by targeting intron 13
(Hs04958893_cn) and intron 16 (Hs05004157_cn), whereas a single
assay was used forMITF (Hs02258756_cn),MET (Hs00305306_cn),
CCND1 (Hs01425024_cn), andCTNNB1 (Hs02393264_cn). TaqMan
copy number reference assay RNase P was used as endogenous refer-
ence gene. DNA isolated from blood samples of healthy donors was
used as control. PCRs were performed in quadruplicate and run on
the ABI Prism 7900HT machine. Results were analyzed using the
Copy Caller software version 1.1 and copy numbers 4 or higher were
considered gene amplifications. The methylation status of the PTEN
promoter was determined after bisulfite conversion using the EZ
DNAMethylation-Gold Kit (Zymo Research, Irvine, CA) by perform-
ing PCR analysis using previously reported primers and protocols with
minor modifications [17]. Multiplex ligation-dependent probe ampli-
fication (MLPA) SALSA kits P005, P006, and P007 were used to pro-
file changes in chromosomal regions as detailed by the manufacturer
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(MRC-Holland, Amsterdam, the Netherlands). Results were analyzed
by Coffalyser v 9.4 software by normalizing to three samples of normal
DNA. The resulting values were categorized as homozygous loss (≤0.3),
loss of heterozygosity (≤0.6), gain (≥1.3), and amplification (≥2).
Materials
The following antibodies were used: anti-pERK1/2 (M8159), anti-
ERK (M5670), and anti-vinculin (V9131) from Sigma (St. Louis,
MO); anti-AKT (610861) from Becton Dickinson; anti-pAKT (4051),
anti-pSRC (2105), anti-pMET (3077), anti–phosphorylated signal trans-
ducer and activator of transcription 3 (STAT3; 9131), anti-pPaxillin
(2541), and anti-pp130CAS (4011S) from Cell Signaling Technology
(Danvers, MA); anti-Src (05-184), anti-p70 S6 kinase (p70S6K;
05-781), anti-pp70 S6 kinase (04-392), and anti-Src homology 2
domain–containing transforming protein (SHC; 06-203) fromUpstate
Biotechnology (Lake Placid, NY); anti-CCND1 (M7155) from Dako
(Glostrup, Denmark); anti-MET (sc-10), anti-STAT3 (sc-483), anti-
CRAF (sc-133), anti-phosphorylated focal adhesion kinase (pFAK;
sc-101679), anti-FAK (sc-932), anti-pSHC (sc-18074-R), and anti-
actin (sc-166) from Santa Cruz Biotechnology (Santa Cruz, CA);
anti-paxillin (P13520) from Transduction Laboratories (Lexington,
KY); anti-p130CAS (ab33539) from Abcam (Cambridge, UK);
anti–breast cancer resistance protein (BCRP; MON9041) and anti–
multidrug resistance protein 4 (MRP4; MON9069) from Monosan
(Valter Occhiena, Torino, Italy); anti-KIT (v-kit Hardy-Zuckerman
4 feline sarcoma viral oncogene homolog; 566) from MBL (Woburn,
MA); and peroxidase-conjugated secondary antibodies anti-mouse im-
munoglobulin (Becton Dickinson) and anti-rabbit immunoglobulin G
(Amersham, Piscataway, NJ) were used. For anti–phosphorylated tyro-
sine (pTyr) immunoprecipitation and MALDI-TOF mass spec-
trometry analysis, samples were processed as previously described
[18,19]. Only proteins identified in at least three separate experiments
were considered.
PLX4032 was obtained by agreement with Plexxikon, Inc (Berkeley,
CA). SU11274/Sugen, UO126, PHA-665752 (Sigma), BMS-354825/
Dasatinib (LC Laboratories, Woburn, MA), JNJ-38877605, SGX-
523 (Selleck, Houston, TX), and E804/Indirubin (Calbiochem,
Gibbstown, NJ) were purchased. After dose-response tests, the drugs
were used at the concentrations indicated.
Data Analysis
Fitted lines were generated using the four-parameter nonlinear re-
gression with a sigmoidal dose response (variable slope), and the IC50
values (growth-adjusted inhibitory concentration of 50%) for inhibi-
tion of cell growth at 72 hours of PLX4032 treatment were calculated
using Prism v 5.0 software. Student’s t test and one-way analysis of
variance (ANOVA) followed by the Bonferroni correction were used
to evaluate statistical significance. Drug interaction was evaluated
as described elsewhere [20] with interaction index values greater than
1 indicating synergism. The reported data are representative of three
independent experiments.
Results
PLX4032 Growth Inhibitory Effects in BRAFV600E-Mutated
Melanoma Cells Are Not Associated with Other Common
Melanoma Gene Alterations Including PTEN Loss
The growth inhibitory effect of PLX4032 was tested in a panel of
27 genetically characterized melanoma cell lines, including 20 lines
that were heterozygous for the V600E BRAF mutation and 7 lines
carrying wild-type BRAF gene. The effect of other genetic alterations,
including mutations in CDKN2A, PTEN, and tumor protein p53
(TP53) and amplification of BRAF and MITF, on melanoma cell
sensitivity to PLX4032 was considered. We found that PLX4032 in-
hibition of cell growth was strictly dependent on the presence of
BRAFV600E and independent of other gene alterations. In fact, 18 of
20 BRAFV600E-mutated melanoma cell lines were sensitive to the com-
pound, with IC50 values ranging between 0.01 and 1 μM, whereas
2 cell lines displayed a poor sensitivity and showed IC50 values that
were approximately 10 μM. The different IC50 values were not asso-
ciated with the mutational profiles of the cell lines, including the
amplification of the BRAF or MITF genes, or to the expression of
KIT protein (Table 1).
Melanoma cell lines LM20 and LM38 showed primary resistance to
PLX4032 lacked p16 and KIT protein expression but showed differ-
ent gene alterations because LM20 cells harbored MITF amplification
and mutated TP53, whereas LM38 lacked p14/ARF gene and PTEN
expression because of gene methylation. PTEN deficiency has been
hypothesized to promote melanoma cell proliferation and survival
through AKT activation, which may decrease the dependency on
ERK signaling. Moreover, PTEN loss has been detected in a melanoma
tissue biopsy obtained from a patient relapsing on treatment with
PLX4032 [13]. When response of melanoma cell lines to PLX4032
concentrations inhibiting cell growth was examined, we found that
the drug produced an accumulation in the G1 phase of cell cycle re-
gardless of PTEN status (Figures 1 and W1). Growth inhibition was
associated with apoptotic cell death, as documented by AK release and
activation of caspase 3, at higher levels in PTEN-positive samples, in-
dicating a role for PTEN in the induction of cell death in response to
PLX4032 (Figure 1, A and B).
Modulation of MAPK and AKT Signaling by
PLX4032 Treatment
To define the cellular response that was associated with PLX4032
sensitivity, we examined the effect of treatment on downstream sig-
naling pathways that regulate cell growth and survival. PLX4032
treatment strongly reduced the levels of pERK and pAKT in most
drug-sensitive cell lines, independently of PTEN status. In addition,
down-regulation of p70S6K, which is activated downstream of the
mammalian target of rapamycin signaling, was detectable in most lines,
and CCND1 expression was downregulated in all drug-sensitive cell
lines, consistently with an accumulation in the G1 phase of the cell
cycle. In contrast, pAKT, pERK, pp70S6K, and cyclin D1 levels were
not affected by the treatment in the resistant LM20 and LM38 cells,
in keeping with the poor antiproliferative and cytotoxic effects
(Figure 1C ).
A resistant cell line (LM17R) was generated by repeated drug ex-
posure from the cell line LM17, which showed extensive cell death
after PLX4032 treatment. LM17R showed reduced sensitivity to the
antiproliferative effect of PLX4032, diminished AK release, caspase 3
activation, and G1 block of the cell cycle, as well as unresponsiveness
of pERK, pAKT, and CCND1 (Figure 2). Sequence analysis con-
firmed the presence of the heterozygous V600E BRAF mutation
and excluded the presence of secondary mutations in exons 11 and
15 and in RAS gene; in addition, the same number of copies of the
BRAF gene as the parental LM17 cells was detected.
To assess whether the MAPK pathway can be modulated down-
stream of mutated BRAF in resistant cells, we tested whether MEK
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Table 1. Genetic Characterization and PLX4032 Sensitivity of the Melanoma Cell Lines.
Melanoma* IC50 PLX4032 (μM)
† BRAF‡ nBRAF 7q34§ nMITF 3p14§ NRAS‡ PTEN TP53 p16 p14/ARF cKIT¶
LM4 0.065 V600E 4 2 wt wt/+ Y236H del del +
LM14 0.128 V600E 2 2 wt wt/+ wt del del −
LM15 0.088 V600E 3 4 wt wt/+ wt del del −
LM16 0.023 V600E 4 10 wt wt/+ wt L65P wt/+ L862L/+
LM17 0.238 V600E 3 3 wt P38S/+ S127F A148T/+ wt/+ −
LM17R 4.044 V600E 3 3 wt +
LM20 8.907 V600E 2 4 wt wt/+ Y234C wt/− wt/+ −
LM21 0.027 V600E 3 3 wt P246S/+ S127F del del +
LM25 0.122 V600E 2 6 wt wt/+ E258K R80stop/− P94L/− −
LM26 1.195 V600E 3 3 wt C105fsX112/− R175H del del −
LM27 0.031 V600E 7 4 wt wt/+ wt IVS2−2A>G/− wt/− +
LM28 0.398 V600E 3 3 wt wt/+ wt del del +
LM30 0.031 V600E 2 2 wt wt/+ wt del del −
LM33 0.057 V600E 2 5 wt wt/+ wt del del −
LM34 0.097 V600E 5 3 wt wt/+ wt A148T/− wt/− −
LM36 1.778 V600E 4 2 wt wt/+ wt del del I798I/−
LM38 8.871 V600E 11 3 wt M/− wt del del L862L/−
LM39 0.153 V600E 2 2 wt wt/+ wt del del −
LM41 0.166 V600E 3 3 wt wt/+ wt wt/− wt/+ −
LM42 0.032 V600E 2 3 wt M/− c993+1 G>A del del −
LM43 0.017 V600E 8 4 wt M/− wt del del L862L/−
LM3 >6.400 wt 3 4 Q61R wt/− wt wt/− wt/− +
LM18 >6.400 wt 2 3 Q61R wt/+ wt del del +
LM19 >6.400 wt 3 9 wt wt/+ wt del del +
LM23 >6.400 wt 2 3 wt wt/+ wt del del −
LM24 >6.400 wt 2 3 Q61R wt/+ wt del wt/+ +
LM32 >6.400 wt 8 3 wt wt/− wt del del −
LM35 >6.400 wt 4 6 wt M/− wt del del +
+, − indicates presence or absence of protein expression; del, homozygous deletion; M, gene methylation; wt, wild-type gene.
Polymorphisms are shown in italics. PLX4032-resistant cell lines are shown in bold.
*Cell lines are numbered according to the list reported in Daniotti et al. [15]. All lines are shown wild-type for PI3KCA exons 9 and 20, GNAQ exon 5, and CDK4 exon 2, except LM17 cells that carry a
K22R mutation in CDK4 exon 2.
†IC50 values were calculated by modeling results of growth inhibition assays using a nonlinear regression curve fit with a sigmoidal dose-response (variable slope).
‡Heterozygous mutations; exons 11 and 15 for BRAF and exons 1 and 2 for NRAS gene were sequenced.
§Gene copy number as evaluated by quantitative PCR as detailed in Materials and Methods.
¶KIT gene exons 9, 11, 13, 14, 17, and 18 were sequenced. Polymorphism L862L (rs3733542) in exon 18 and the silent mutation I798I in exon 17 were detected. KIT protein expression was evaluated
by Western blot.
Figure 1. Effects of PLX4032 on BRAFV600E-mutated melanoma cells expressing or lacking PTEN. (A) Inhibition of cell growth (72 hours),
AK release (72 hours), and activated caspase 3 (48 hours) after treatment with PLX4032 (3.2 μM). The percentage of growth was calculated
as: (OD570 of wells that contained the drug/OD570 of the drug-free wells) × 100. Error bars, SD. (B) Percentages of cells in sub G1, G1, S,
and G2/M phases of cell cycle after 24 hours of treatment with PLX4032 (3.2 μM). (C) Modulation of phospho-signaling after 24 hours of
PLX4032 treatment (3.2 μM).
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inhibition affected pERK levels and cell proliferation. Treatment
with the MEK1/2 inhibitor UO126 reduced pERK signal and inhib-
ited proliferation in LM20 and LM38 as well as in LM17R cells
compared with that in LM17 (Figure 3, A and B), indicating that
these cell lines retained the susceptibility to MEK inhibition.
A shift in signaling from BRAF to CRAF after BRAF inhibition
has been described in melanoma cells, with CRAF mediating ERK
activation [21]. Therefore, we silenced CRAF in LM38 cells using
specific siRNA to test whether the sensitivity to PLX4032 increased
by reducing CRAF levels. The CRAF siRNA downregulated CRAF
protein levels without affecting pERK levels and cell sensitivity
to PLX4032. Similar results were obtained also in LM17R cells
(Figure 3, C and D).
Molecular Characterization of Melanoma Cell Lines Showing
Resistance to PLX4032
To identify new potential markers that are associated with PLX4032
resistance and candidate genes, the MLPA analysis was used to geneti-
cally characterize the resistant melanoma cell lines. Several probes
showed values indicating gene gain or loss (Figure W2). Amplification
of CCND1 at 11q13 and of CTNNB1 at 3p21 was detected in LM20
cells, whereas the LM38 line showed a different pattern of alterations,
including MET amplification at 7q31. MET, CCND1, and CTNNB1
gene amplifications in LM38 and in LM20 were confirmed by FISH
analysis (Figure 4A and data not shown) and by using quantitative PCR
assessing gene copy number (Table W1). MLPA analysis showed no
difference in the pattern of alterations between LM17R and LM17,
indicating that the acquisition of resistance to PLX4032 was not asso-
ciated to gain or loss of the tested genes.
To further explore the mechanisms of PLX4032 resistance, a
proteomic-multiplexed analysis of pTyr signaling and antibody valida-
tion was used to screen pTyr proteins that were modulated by treatment
in PLX4032-sensitive and -resistant melanoma cells. We observed a
high degree of heterogeneity in the pTyr profiles in the different cell
lines (Figure W3). To identify the most abundant phosphorylated pro-
teins in LM20 and LM38 cell lines, protein bands from anti-pTyr
immunoprecipitates of cell lysates were resolved in SDS-PAGE, excised
from preparative silver-stained gel, and processed forMALDI-TOFmass
spectrometry analysis. The identified proteins indicated that pTyr-based
cell signaling was activated in the v-src sarcoma viral oncogene homolog
(SRC)/FAK axis in LM20 cells, whereas it was prevalently activated in
the MET axis in LM38 cells (Figure 4C ). These data were consistent
withMET gene amplification in LM38 cells andCTNNB1 amplification
in LM20 cells for the role of SRC activity in regulating CTNNB1 sig-
naling. Immunoblot analysis confirmed the presence of the phosphory-
lated MET receptor in LM38 cells, whereas the phosphorylated form
of STAT3, which is activated downstream of SRC, was detectable in
LM20 cells. The MET and STAT3 proteins were present but not
phosphorylated in the other cell line. In particular, high levels of non–
tyrosine-phosphorylated STAT3 were detected in LM38 cells, and both
lines showed high pSRC levels, which were not reduced by PLX4032
treatment (Figure 4B).
To define whether PLX4032 resistance was mediated by the increased
expression of ABC transporters, we assessed protein expression of
ABCB1/Gp170, ABCC1/MRP1, ABCC2/MRP2, ABCC4/MRP4,
and ABCG2/BCRP in the resistant melanoma cell lines. Differential ex-
pression was observed for BCRP and MRP4 (Figure W4). However,
BCRP overexpression did not result in resistance to PLX4032 as shown
by using a mutant BRAF isogenic model system [22]. In addition,
topotecan, a well-known MRP4 substrate, displayed a similar effect in
LM17 and LM17R cells despite increasedMRP4 levels (data not shown).
Thus, PLX4032 resistance is not determined by ABC transporters.
MET and SRC as Additional Targets for Combined Treatment
with PLX4032
On the basis of the results of molecular profiling, MET and SRC
represented new candidate targets expressed at high levels and acti-
vated in LM38 and LM20 melanoma cells intrinsically resistant to
PLX4032. We thus tested the effect of combining PLX4032 with
drugs that inhibited MET and SRC kinases.
The MET inhibitor SU11274 significantly inhibited the prolifera-
tion of most of the melanoma cell lines that were examined, including
PLX4032-resistant lines, with IC50 values of approximately 10 μM
(data not shown). The combined treatment with SU11274 and
PLX4032 produced a synergistic interaction when tested in LM38
cells (interaction index = 2.5), and growth inhibition was associated
with an accumulation of cells in G1 and AK release in the absence
of caspase 3 activation (Figure 5A and not shown). The potentiating
effect that was obtained by the concomitant inhibition was evident
also when other MET inhibitors were tested (Figure 5B). After the
cotreatment with SU11274 and PLX4032, pERK and pAKT were
not downregulated; in contrast, we found a strong down-regulation
of MET signaling through pFAK and pSHC (Figure 5C ).
Figure 2. Selection of PLX4032-resistant variant LM17R by long-
term exposure of LM17 cells to PLX4032. (A) Growth curves show-
ing decreased sensitivity to PLX4032 in LM17R cells. Calculated IC50
values were 0.2 and 4 μM for LM17 and LM17R, respectively.
(B) Enhanced ERK and AKT signaling in the resistant variant LM17R.
Expression levels as evaluated by Western blot analysis in parental
and resistant cells treatedwith PLX4032 (3.2 μMfor 24 hours). (C) Cell
growth, cell death, caspase 3 staining, and cell cycle analysis were
tested at 72, 48, and 24 hours of treatment with PLX4032 (3.2 μM).
*P < .0001 by Student’s t test.
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Because MET is involved in tumor invasion, we evaluated the
effects of the combined treatment on the ability of melanoma cells
to invade Matrigel and migrate in vitro. LM38 melanoma cells were
highly responsive to the MET ligand hepatocyte growth factor (HGF),
as the addiction of HGF determined a significant increase in the
number of cells that migrated through the Matrigel layer (not shown),
further confirming the role of MET signaling in mediating the invasive
capacity in these cells. Indeed, blocking MET signaling by treatment
with SU11274 alone or in combination with PLX4032 strongly inhib-
ited Matrigel invasion. Notably, a moderate effect was observed after
treatment with PLX4032, indicating that BRAF inhibition, although
not affecting cell growth, may alter the invasive activity of melanoma
cells, even in the presence of exogenous HGF (Figure 5D). Moreover,
LM38 cells produced HGF (data not shown), thus suggesting that
an autocrine loop contribute to MET pathway constitutive activa-
tion. In addition, the combined drugs downregulated the expression
of β1-integrin, the receptor for extracellular matrix laminin that is
involved in adhesive and invasive cellular processes (Figure 5E ).
Scratch wound assays showed that the combination of PLX4032 with
SU11274 prevented wound closure, whereas the single drugs im-
paired wound healing to a limited extent, confirming the effect of
the combination on cell migration (Figure 5F).
To confirm that MET inhibition can cooperate with BRAF inhibi-
tion siRNA silencing of MET was tested. A synergic effect on cell pro-
liferation was detected (interaction index = 1.36), and down-regulation
of MET and SHC signal was shown, whereas pERK and pAKT levels
were maintained (Figure 6, A and B).
To assess the functional relevance of the SRC pathway in LM20
cells, the BMS-354825 multikinase inhibitor targeting SRC family
kinases was used. When tested in the panel of melanoma cell lines,
BMS-354825 displayed a poor inhibitory effect on cell growth, and
its antiproliferative effect was not related to the expression of KIT pro-
tein, which is one of the kinases targeted by the compound (not
shown). BMS-354825 showed a weak inhibitory effect on cell growth
in LM20 cells, whereas the combination of BMS-354825 with
PLX4032 displayed significant antiproliferative and cytotoxic effects
(interaction index = 2.1). Another SRC inhibitor, E804, exerted an
additive effect with PLX4032, further corroborating the role of SRC
signaling in LM20 cells (Figure 7A). Treatment with BMS-354825
downregulated the levels of phosphorylated SRC protein and of
the downstream targets paxillin and p130CAS; in addition, BMS-
354825 reduced pFAK levels. In contrast, no effect was detectable
on pERK and pAKT levels also with this drug combination, suggesting
that it is not a necessary requirement to impair cell proliferation (Fig-
ure 7B and data not shown). The combined treatment with PLX4032
and BMS-354825 decreased MMP-2 production by LM20 melanoma
cells, which was measured using gelatin-gel zymography (Figure 7C),
and reduced the expression of β1-integrin (Figure 7D).
Discussion
It is not yet known how other concurrent genetic alterations in ad-
dition to BRAF mutations may affect the clinical efficacy of the
BRAF inhibitor PLX4032 in metastatic melanoma and whether a
classification level can be defined for the molecular profiles that are
Figure 3. Resistance to PLX4032 is independent of MEK and CRAF. (A) The proliferation of melanoma LM20, LM38, LM17R, and LM17
cells was similarly inhibited by 72 hours of treatment with UO126 (IC50 values: 9.7, 4, 6.3, and 16.1 μM, respectively). (B) Levels of pERK are
downregulated after 24 hours of incubation with UO126 (25 μM). (C) Western blot analysis of LM38 and LM17R cells that were transfected
with CRAF or control siRNA for 24 hours before being treated for 24 hours with PLX4032 (3.2 μM), showing CRAF protein levels down-
regulated to 14% and to 20%, respectively, as determined by quantification of the signal by Image Quant v5.2 software. (D) LM38 and
LM17R cells were treated for 24 hours with CRAF or control siRNA before 72 hours of treatment with PLX4032 (3.2 μM). Absorbance at
570 nm after MTT staining is shown, indicating that CRAF inhibition does not increase sensitivity to PLX4032.
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associated with primary resistance. Although BRAF, NRAS, and KIT
mutations are mutually exclusive, mutated BRAF melanoma may carry
common alterations in CDKN2A, PTEN, and TP53 genes, as well as
alterations of CDK4, CTNNB1, FGFR2, MITF, ERBB4, MMP, and
GRIN2A genes [3,15,23], and other potential driver mutations still
poorly characterized [24]. Here, we show that, apart from BRAF
mutation, the gene alterations that are common in melanoma, such
as PTEN and TP53 mutations, and BRAF and MITF amplification,
are not associated with PLX4032 sensitivity in a large panel of geneti-
cally characterized short-term melanoma cell lines.
Studies performed on melanoma tissue from few patients relapsing on
treatment with PLX4032 have ruled out the occurrence of additional
secondarymutations in the BRAF gene and have reported the overgrowth
ofNRASmutated [11], PTEN deleted [13], and C121SMEK1mutated
[14] metastases in different individual cases. These results suggest that
the mechanisms that mediate acquired resistance rely on different genetic
alterations thatmay include the overgrowth of preexisting genetic variants
selected by the treatment as well as de novo mutations.
The in vitro studies on primary resistance to BRAF inhibitors have
detected CCND1 gene amplification in cell lines that were resistant
to the BRAF inhibitor SB590885 [25]. Other studies have identi-
fied different changes in MEK1 and BRAF T529N causing resistance
to PLX4720 [26,27]. Melanoma cell lines carrying homozygous
BRAFV600E mutation were shown to be more sensitive to PLX4032
than those carrying heterozygous BRAFV600E mutation [28–30]. Al-
though homozygosity is rare, the 7q34 chromosomal region where
the BRAF gene is located is frequently amplified in melanoma lesions
and especially in BRAFV600E-mutated melanomas [31]. Amplification
of the mutated BRAF allele was detected in association with acquired
resistance toMEK inhibitors in a melanoma cell line in a previous study
[32]. In our panel of melanoma cell lines, BRAF gene amplification
was detected in 30% of the cell lines, including the resistant LM38
melanoma model, whereas in the resistant variant LM17R, which
was obtained by long-term exposure to PLX4032 in vitro, the BRAF
gene was not amplified compared with the parental cell line.
In addition to BRAF gene amplification, LM38 melanoma cells re-
sistant to PLX4032 lacked PTEN. We detected lower levels of cyto-
toxicity in PTEN-negative melanoma cells after exposure to PLX4032
compared with melanomas with intact PTEN, but a similar block
of cell cycle, suggesting a role for PTEN in the cytotoxic effect of
PLX4032. This finding is in agreement with studies reporting that
PTEN loss contributes to PLX4720 resistance by suppressing BIM-
mediated apoptosis [33].
The PLX4032-resistant line LM20 harbored amplified MITF gene.
MITF gene amplification was detected in 30% of our BRAFV600E-
mutated cell lines. Unexpectedly, however, melanomas with amplified
MITF (≥4 copies) showed lower IC50 values than melanomas without
MITF amplification when only cell lines carrying two gene copies
were considered (0.05 vs 0.4 μM, P = .0013), suggesting that MITF
amplification does not contribute to PLX4032 resistance.
Because it has been shown that kinase inhibitors are able to interact
with members of the ABC family of transporters and that ABC trans-
porters can mediate resistance to kinase inhibitors [34,35], we tested
whether BCRP and MRP4 showing overexpression in resistant cells
play a role in PLX4032 resistance. The results of these experiments
do not indicate a role for BCRP or MRP4 in resistance to PLX4032.
By expanding the genetic characterization to the analysis of altered
chromosomal regions by MLPA, the amplification of MET gene in
LM38 cells and of CCND1 and CTNNB1 genes in LM20 cells was
detected. This pattern was consistent with the pTyr profiling analysis as
detected by MALDI-TOF indicating activated MET and SRC signal-
ing. The amplification of theMET gene has been reported inmelanoma
[36] along with chromosome 7 polysomy [31]. The amplification of
Figure 4. Molecular characteristics of the PLX4032-resistant LM20
and LM38 cell lines. (A) FISH analysis with orange labeled probe tar-
geting MET gene and green control probe in LM38 cells. Four green
and more than eight orange signals are shown in cells indicated by
the arrows. (B) Detection of pMET, pSRC, and pSTAT3 signals after
24 hours of treatment with PLX4032 (3.2 μM) in LM38 and LM20
cells by Western blot analysis. (C) Identification of some relevant
immunoaffinity-purified proteins from LM38 and LM20 cell lines.
Top: Coomassie blue staining of anti-pTyr affinity-purified proteins
from LM38 cells. Bottom: Silver staining of anti-pTyr affinity-purified
proteins from LM20 cells. Protein extracts were incubated with anti-
pTyr agarose-conjugated antibody. Bound proteins were washed,
eluted, and resolved by 4% to 12%SDS-PAGE.Mw indicatesmolecu-
lar weight markers. Swiss Prot ID indicates accession number.
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CCND1 was detected in approximately 25% melanoma bearing
mutated BRAF [37]. AlthoughCTNNB1mutations have been reported
in melanoma, gene amplification was not formerly shown, although it
was detected by MLPA in melanoma lesions [38].
Epigenetic changes providing compensatory signaling to bypass
BRAF blockade and activate ERK are associated with acquired resis-
tance to BRAF inhibitors. Several different mechanisms have been
described, including the activation of a platelet-derived growth factor
receptor β, IGF1R/phosphoinositide 3-kinase and MAP3K8/COT
signaling [11–13]. Moreover, increased CRAF protein levels and
switching from BRAF to CRAF dependency has been associated with
the in vitro acquired resistance to AZ628 BRAF inhibitor [21]. Al-
though our data do not support a role for CRAF in resistance to
PLX4032, in the current study, LM17R cells with acquired resis-
tance to PLX4032 showed increased IGFR1 signaling and consis-
tently higher levels of pAKT compared with that of the parental
LM17 cell line (data not shown). Up-regulation of IGF1R signaling
was reported to occur in two of four melanoma cell variants that were
selected in vitro for resistance to the 885 BRAF inhibitor [13], there-
fore appearing as a rather common mechanism by which melanoma
cells compensate BRAF inhibition.
Targeting other signaling molecules in crucial pathways may rep-
resent an approach to enhance the clinical impact of treatment with
PLX4032. Preclinical studies showed that MEK inhibitors in com-
bination with PLX4720 reduced cell growth and pERK expression
[12] and may prevent the emergence of resistant clones [26].
We show that simultaneously targeting multiple pathways may rep-
resent a promising option for treating PLX4032-resistant melanomas.
Figure 5. Cotreatment with MET inhibitor and PLX4032 inhibits growth, invasion, and migration of LM38-resistant melanoma. (A) Growth
inhibition (72 hours), AK release (72 hours), and cell cycle (24 hours) in LM38 cells treated with PLX4032 and/or SU11274. *P < .0001 by
one-way ANOVA followed by the Bonferroni correction. ★: interaction index = 2.5. (B) The inhibitory effect of PLX4032 combined with
JNJ-38877605 (J), PHA-665752 (PHA), and SGX-523 (SGX) on proliferation is shown. ★: interaction index = 2.2, 1.22, and 1.33, respec-
tively. P < .0001 by one-way ANOVA followed by the Bonferroni correction. (C) Western blot analysis showing the regulation of down-
stream MET targets in LM38 cells after 24 hours of treatment with PLX4032 and/or SU11274. (D) The Matrigel cell invasion assay
showing the effect of exposure to PLX4032, SU11274 or both in LM38 cells. The percent inhibition of migration at 24 hours with or
without HGF compared with that of untreated cells is shown. *P < .0001 compared with treatment with PLX4032 by Student’s t test.
(E) FACS analysis of β1-integrin expression after 24 hours of exposure to PLX4032 and/or SU11274 in LM38 cells. Mean fluorescence
intensity after treatment is indicated. (F) Scratch wound assay showing closure of a scratch wound in cultured LM38 cells under control
conditions or in the presence of PLX4032, SU11274, or both for 72 hours. Medium was replaced every day to remove detached dead
cells. Magnification, ×2.5. − indicates untreated control; P, PLX4032 (3.2 μM); S, SU11274 (10 μM).
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Figure 6. MET silencing increases sensitivity to PLX4032 in LM38 PLX4032 resistant cell line. (A) LM38 cells were treated for 96 hours
with MET or control siRNA and with PLX4032 (3.2 μM). After MTT staining, the percentage of cell growth was calculated compared with
the untreated control. *P < .0001 by one-way ANOVA followed by the Bonferroni correction. (B) Western blot analyses of LM38 cells
showing modulation of MET signaling after 96 hours of the indicated treatments. MET protein levels were downregulated to 20%, as
determined by quantification of the signal by Image Quant v5.2 software.
Figure 7. Cotreatment with SRC inhibitors and PLX4032 inhibits LM20 melanoma cell growth and downregulates MMP-2 and β1-integrin.
(A) Growth inhibition, AK release (72 hours), and activated caspase 3 (48 hours) in LM20 cells that were treated with PLX4032 and/or
BMS-354825. *P < .0001 by one-way ANOVA followed by the Bonferroni correction. ★: interaction index = 2.1. Bottom right, growth
inhibitory effect of PLX4032 combined with the SRC inhibitor E804. *P < .0001 compared with single treatments by Student’s t test.
(B) Western blot analysis showing regulation of downstream SRC targets in LM20 cells after 24 hours of treatment with PLX4032 and/or
BMS-354825. (C) Gelatin zymography detecting MMP-2 in supernatants from LM20 cells collected after 24 hours of exposure to PLX4032,
BMS-354825, or their combination. MMP-2 band was detectable at 72 kDa. (D) FACS analysis of β1-integrin expression after 24 hours of
exposure to PLX4032 and/or BMS-354825 in LM20 cells. Mean fluorescence intensity after treatment is indicated. − indicates untreated
control; B, BMS-354825 (100 nM); E, E804; P, PLX4032 (3.2 μM); pos, positive control.
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Treatment with the MET inhibitor SU11274 inhibited the growth of
LM38 cells harboring constitutively activated MET and the combina-
tion with PLX4032 increased this effect. The treatment specifically
inhibited MET kinase activity and downstream signaling. It is possible
that the effects of SU11274 resulted from the inhibition of additional
kinases involved in MET-dependent downstream responses or reduced
because of off-target effects. SU11274 was reported to reduce prolifera-
tion in some melanoma cell lines [39,40] and HGF-induced motility
and invasion in cell models of other tumor types. MET inhibition with
other drugs or by specific siRNA confirmed the role of MET signaling
in LM38 cells resistant to PLX4032. MET overexpression has been
shown to contribute to resistance to cytotoxic drugs in ovarian cancer
[41]. Although MET gene mutations are very rare [39,40,42], MET
gene amplification [36] and autocrine production of HGF [43] occur
frequently in melanoma. MET activation has been associated to NRAS
mutation in melanoma [44]. In addition, MET signaling is upregulated
by MITF [45].
BMS-354825, which is a multikinase inhibitor targeting the SRC
family kinases, induced apoptosis in LM20 cells when combined
with PLX4032. BMS-354825 was reported to downregulate activated
SRC, FAK, and EphA2 in melanoma cells and to inhibit proliferation
in some melanoma cell lines [46,47]. However, BMS-354825 alone
did not significantly affect the growth of LM20 cells. Likely, STAT3
activation regulated an oncogenic signaling in LM20 cells. Moreover,
the combination of PLX4032 with SU11274 or with BMS-354825
reduced the invasive and migratory capacities, consistently with in-
hibition of MMP-2 activity and the expression of β1-integrin, suggest-
ing that the drug combination may result in an inhibitory effect on
melanoma growth and dissemination. These results are consistent with
a regulatory role of MAPK signaling on the expression of MMPs [48]
and β1-integrin [49]. Furthermore, these data revealed that cell func-
tions other than proliferation and survival are reduced by exposure to
PLX4032, suggesting that they are governed by signaling molecules
affected by PLX4032 treatment. Because of these effects, we can
hypothesize that synergic inhibition of cell proliferation of PLX4032
with MET or SRC inhibitors results from some inhibitory effects on
MAPK signaling exerted by PLX4032, which are overridden by com-
pensatory routes exerted by other MEK activators when used as a
single treatment.
SRC and MET have been implicated in the development and pro-
gression of several types of tumors as a result of the interaction with
receptor tyrosine kinases and their downstream effectors leading to
proliferation, cell growth, survival, motility, migration, and angio-
genesis. In particular, aberrant MET activation, due to overexpression,
mutations, or gene amplification, has been associated with poor clinical
outcome and drug resistance in lung, hepatic, renal, and colorectal
carcinoma [50]. The nonreceptor protein tyrosine kinase SRC acts as
a signal transducer from the cell surface receptors by sequential phos-
phorylation of tyrosine residues on different substrates. SRC is a key
molecule in tumor progression providing oncogenic signals for cell
survival, epithelial-mesenchymal transition, mitogenesis, invasion,
angiogenesis, and metastasis. Aberrant expression and activation of
SRC occur in breast, prostate, lung, and colorectal carcinomas, in
association with poor clinical outcome, and have stimulated interest
in using SRC kinase inhibitors as therapeutic cancer agents, some of
which have entered clinical experimentation [51].
Our results highlight the complexity of signaling in melanoma and
support the relevance of genetic and proteomic profiling to build
rational combination treatments with targeted agents.
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Figure W1. Histograms for cell cycle of the resistant cell lines LM20, LM38, and the sensitive cell line LM42 after 24 hours of treatment with
PLX4032 (3.2 μM). G1 and G2/M are represented by the two filled peaks, with the dashed peak in between corresponding to the S phase.
Figure W2. Gene gain or loss as detected by MLPA analysis. Re-
sults obtained with PLX4032-resistant LM20, LM38, and LM17R
melanoma cells and PLX4032-sensitive LM17, LM26, LM41, LM42,
and LM43 melanoma cells are shown.
Table W1. TaqMan Copy Number Analysis of MET, CCND1, and CTNNB1 Genes.
Melanoma nMET 7q31 nCCND1 11q13 nCTNNB1 3p21
LM20 2 8 7
LM38 6 2 2
LM17R 3 2 2
LM17 2 2 2
Gene copy number as evaluated by quantitative PCR as detailed in Materials and Methods.
Figure W3. Phosphotyrosine protein separation of melanoma cell lines before and after PLX4032 treatment. Anti-pTyr immunoblot of
whole-cell extracts isolated from control cells or cells that were treated with PLX4032 (3.2 μM for 24 hours) and resolved by 4% to 12%
SDS-PAGE is shown.
Figure W4. Expression of membrane BCRP and MRP4 transporters
of the ABC superfamily in PLX4032-resistant and PLX4032-sensitive
cell lines.
